Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | LPL | P06858 | 12/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243207 | 0.89 | CA1 (0.61) | CA1CA2CA9LPLLIPG | |
| SCHEMBL25358250 | 0.84 | CYP19A1 (0.49) | CA1CA2CA9LPLLIPG | |
| SCHEMBL31276809 | 0.84 | CYP19A1 (0.49) | CA1CA2CA9LPLLIPG | |
| SCHEMBL321437 | 0.83 | LPL (0.53) | CA1CA2CA9LPLLIPG | |
| SCHEMBL25658494 | 0.82 | CA1 (0.54) | CA1CA2CA9LPLLIPG | |
| SCHEMBL5899727 | 0.82 | LPL (0.65) | CA1CA2CA9LPLLIPG | |
| SCHEMBL623833 | 0.82 | CA1 (0.54) | CA1CA2CA9LPLLIPG | |
| SCHEMBL171897 | 0.82 | CA1 (0.44) | CA1CA2CA9LPLLIPG | |
| SCHEMBL368960 | 0.81 | LPL (0.71) | CA1CA2CA9LPLLIPG | |
| SCHEMBL17423566 | 0.81 | CA1 (0.53) | CA1CA2CA9LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481831-B1 | 4-AMINOPYRAZOLO[3,4-D]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| EP-3481831-B1 | 4-AMINOPYRAZOLO[3,4-D]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-03 | — | — | US | disclosed |
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-03 | — | — | US | disclosed |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| WO-2016154998-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE, MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 安润医药科技（苏州）有限公司 | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | ITK, BTK, TYK2 | CA1 4798/4885CA2 2691/4885CA9 3465/4885 |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | BTK, ITK, TYK2 | CA1 4824/4885CA2 3000/4885CA9 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.